Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis
When Evommune went public late last year, it said data from a proof-of-concept test of one of its atopic dermatitis drug candidates would come in the first half of 2026. The results are in, with the company reporting the biologic medicine met the main …